5/8
07:08 am
swtx
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference [Yahoo! Finance]
Medium
Report
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference [Yahoo! Finance]
5/8
07:00 am
swtx
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
Medium
Report
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
5/6
09:36 am
swtx
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/6
08:06 am
swtx
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $74.00 price target on the stock.
Medium
Report
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $74.00 price target on the stock.
5/3
09:08 am
swtx
Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation [Yahoo! Finance]
Low
Report
Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation [Yahoo! Finance]
5/2
05:31 pm
swtx
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $75.00 price target on the stock, up previously from $70.00.
Medium
Report
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $75.00 price target on the stock, up previously from $70.00.
5/2
06:39 am
swtx
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates [Yahoo! Finance]
Medium
Report
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates [Yahoo! Finance]
5/2
06:30 am
swtx
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
Medium
Report
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
4/25
02:32 pm
swtx
SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear [Seeking Alpha]
Low
Report
SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear [Seeking Alpha]
4/24
01:37 pm
swtx
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
Low
Report
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
4/24
01:31 pm
swtx
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Low
Report
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
4/22
09:22 am
swtx
Global Desmoid Tumors Drug Pipeline Research Report 2024: Therapeutic Assessment by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
Medium
Report
Global Desmoid Tumors Drug Pipeline Research Report 2024: Therapeutic Assessment by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
4/19
04:11 pm
swtx
SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners [Seeking Alpha]
Medium
Report
SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners [Seeking Alpha]
4/18
07:23 am
swtx
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024 [Yahoo! Finance]
Low
Report
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024 [Yahoo! Finance]
4/18
07:00 am
swtx
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
Low
Report
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
3/6
08:40 am
swtx
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its price target raised by analysts at HC Wainwright from $73.00 to $74.00. They now have a "buy" rating on the stock.
Medium
Report
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its price target raised by analysts at HC Wainwright from $73.00 to $74.00. They now have a "buy" rating on the stock.
3/6
08:10 am
swtx
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its price target raised by analysts at JPMorgan Chase & Co. from $73.00 to $74.00. They now have an "overweight" rating on the stock.
Medium
Report
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its price target raised by analysts at JPMorgan Chase & Co. from $73.00 to $74.00. They now have an "overweight" rating on the stock.
3/4
06:38 am
swtx
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN [Yahoo! Finance]
Low
Report
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN [Yahoo! Finance]
3/4
06:30 am
swtx
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
Medium
Report
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
2/29
09:10 am
swtx
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its price target raised by analysts at Barclays PLC from $47.00 to $63.00. They now have an "overweight" rating on the stock.
Low
Report
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) had its price target raised by analysts at Barclays PLC from $47.00 to $63.00. They now have an "overweight" rating on the stock.
2/29
08:40 am
swtx
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors [Yahoo! Finance]
Low
Report
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors [Yahoo! Finance]
2/29
08:30 am
swtx
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
Low
Report
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
2/27
07:25 am
swtx
SpringWorks Therapeutics Inc (SWTX) Reports Q4 and Full Year 2023 Financial Results [Yahoo! Finance]
Medium
Report
SpringWorks Therapeutics Inc (SWTX) Reports Q4 and Full Year 2023 Financial Results [Yahoo! Finance]
2/27
06:40 am
swtx
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates [Yahoo! Finance]
Medium
Report
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates [Yahoo! Finance]
2/27
06:30 am
swtx
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
Medium
Report
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates